LICENSING AGREEMENTS (Details Textual)			1 Months Ended			12 Months Ended
	Apr. 03, 2014 USD ($)	May. 02, 2012 USD ($)	Jun. 25, 2015 USD ($)	Jun. 30, 2011 USD ($) $ / shares shares	Mar. 31, 2011 USD ($) shares	Dec. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2014 USD ($) $ / shares shares	Mar. 31, 2016 USD ($)	Oct. 02, 2015 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($) $ / shares	Dec. 31, 2013 $ / shares
License Agreements [Line Items]
Derivative Liability										$ 300,000	$ 400,000
Derivative Liability Expense							$ 0
Common Stock, Shares Authorized | shares						225,000,000	225,000,000
Royalties percentage		50.00%
Minimum [Member]
License Agreements [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 1.66	$ 1.85					$ 1.85
Maximum [Member]
License Agreements [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 65.60	$ 65.60				$ 3.39	$ 124.20
Dalhousie University [Member]
License Agreements [Line Items]
Maintenance Fee Obligation Waived	$ 500,000
Dalhousie University [Member] | Patent Coverage Available [Member]
License Agreements [Line Items]
Royalty Rate, Percent of Net Sales	5.00%
Dalhousie University [Member] | Data Protection Available [Member]
License Agreements [Line Items]
Royalty Rate, Percent of Net Sales	3.00%
iCo [Member]
License Agreements [Line Items]
Class of Warrant or Right Issued				200,000			123,649
Convertible Debt, Fair Value Disclosures				$ 200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 0.95
Percent of Companies Issued and Outstanding Share Capital				6.14%
Dilution Rate				2.50%
Pre Money Valuation Minimum				$ 30,000,000
Derivative Liability				800,000
Derivative Liability Expense						$ 0
Common Stock, Shares Authorized | shares						654,486
Milestone Payments						$ 32,000,000
iCo [Member] | Achievement of Milestoe Marks [Member]
License Agreements [Line Items]
Licenses Revenue						100,000,000
iCo [Member] | Exclusive License Rights [Member]
License Agreements [Line Items]
License Costs				1,700,000
iCo [Member] | Cash Payment [Member]
License Agreements [Line Items]
License Costs				$ 500,000
iCo [Member] | Ordinary Shares [Member]
License Agreements [Line Items]
Stock Issued During Period, Shares, Other | shares				600,000
Stock Issued During Period, Value, Other				$ 1,000,000
Shares Issued, Price Per Share | $ / shares				$ 1.72
Yissum [Member] | Research and Development Arrangement [Member]
License Agreements [Line Items]
Increase In Royalties On Net Sales Of Product Percentage			3.00%
Milestone Payments for license fees			$ 4,500,000
Annual Research Program Fund									$ 400,000
Accrued Annual Research Fee			$ 200,000
License And Research Agreement, Effective Date			Jun. 25, 2020
Yissum [Member] | Maintenance Fee [Member] | Research and Development Arrangement [Member]
License Agreements [Line Items]
Annual Increment In License Cost, Percentage			30.00%
Yissum [Member] | Maintenance Fee [Member] | Minimum [Member] | Research and Development Arrangement [Member]
License Agreements [Line Items]
License Costs			$ 30,000
Yissum [Member] | Maintenance Fee [Member] | Maximum [Member] | Research and Development Arrangement [Member]
License Agreements [Line Items]
License Costs			$ 100,000
Kadouche [Member] | Cash Payment [Member]
License Agreements [Line Items]
License Costs					$ 20,000
Kadouche [Member] | Ordinary Shares [Member]
License Agreements [Line Items]
Stock Issued During Period, Shares, Other | shares					800,000
Stock Issued During Period, Value, Other					$ 700,000
Lonza [Member]
License Agreements [Line Items]
Royalty Rate, Percent of Net Sales		1.00%
Royalty Rate Net Selling Price Of The Product		1.50%
Lonza [Member] | Annual Payments - License Cost [Member]
License Agreements [Line Items]
License Costs		$ 500,000
Lonza [Member] | Annual Payments, Sublicense [Member]
License Agreements [Line Items]
License Costs		100,000
Lonza [Member] | Cell Line Payments [Member]
License Agreements [Line Items]
License Costs		$ 3,000
Royalty Rate, Percent of Net Sales		2.00%
Shire BioChem [Member]
License Agreements [Line Items]
Effect on Future Cash Flows, Amount						$ 26,000,000
Mab Life SAS [Member]
License Agreements [Line Items]
Royalty Rate, Percent of Net Sales						0.60%
Payments to Acquire Businesses, Gross						$ 200,000	$ 100,000
Business Acquisition, Consideration payable, Gross						$ 600,000
Installments Of Consideration Payment, Number						6
Subsequent Event [Member] | Yissum [Member] | Research and Development Arrangement [Member]
License Agreements [Line Items]
Accrued Annual Research Fee								$ 200,000